Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
95 hedge funds and large institutions have $200M invested in Merrimack Pharmaceuticals, Inc. in 2013 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 43 increasing their positions, 17 reducing their positions, and 13 closing their positions.
153% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 17
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
7% more funds holding
Funds holding: 89 → 95 (+6)
11% less call options, than puts
Call options by funds: $213K | Put options by funds: $239K
35% less capital invested
Capital invested by funds: $310M → $200M (-$110M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$10.3M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.99M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.17M |
| 4 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$4M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$3.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$6.64M |
| 2 |
FAM
Fred Alger Management
New York
|
-$5.28M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$3.77M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.52M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1.17M |
MACK Hedge Fund Activity: Q3 2013 in Review
95 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q3 2013, worth a combined $200M — down 35% from $310M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new MACK positions and 13 closed out — a net gain of 7 holders — while 43 added to existing stakes and 17 trimmed.
The largest buyer was Jennison Associates, adding an estimated $10.3M. The largest seller was Credit Suisse, cutting an estimated $6.64M.
- 95 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q3 2013, up from 89 in Q2 2013.
- Funds reported $200M of Merrimack Pharmaceuticals, Inc. stock for Q3 2013, down 35% quarter-over-quarter.
- 20 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q3 2013 and 13 closed out, a net change of +7 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q3 2013 was Jennison Associates, an estimated $10.3M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q3 2013 was Credit Suisse, an estimated $6.64M sold.
Based on aggregated 13F filings for Q3 2013.